1. Introduction {#sec1}
===============

Idiopathic dilated cardiomyopathy (DCM) is a cardiac muscle disease of unknown origin that is characterized by ventricular chamber enlargement and systolic dysfunction with thinning of the left ventricular wall. DCM leads to progressive heart failure and a decline in left ventricular contractile function, conduction system abnormalities, thromboembolism, and sudden or heart failure-related death; only 50% of DCM patients survive more than 5 years beyond their initial diagnosis \[[@B1], [@B2]\]. Coronary artery disease, viral myocarditis, thyroid disease, immunologic processes, and toxins are known causes of DCM; however, the underlying pathology is not known in most cases \[[@B3]--[@B5]\]. In a population-based study, the prevalence of DCM was estimated to be 36.5 cases per 100,000, and 20--50% of these cases are familial \[[@B6]--[@B8]\]. Candidate gene analysis revealed that the cardiac actin encoding gene *ACTC1* mutations were the first sarcomeric gene mutations that caused DCM \[[@B9]\]. To date, mutations have been found in at least six genes encoding sarcomeric proteins: *β*-myosin heavy chain, cardiac myosin binding protein C, titin, cardiac actin, *α*-tropomyosin, cTnT, and cTnC \[[@B9]--[@B15]\].

The *TNNT2* gene (OMIM number \*191045) encodes the protein cardiac TnT, which contains 15 exons and spans 25 kb on chromosome 1q32 \[[@B16]\]. Mutations in the *TNNT2* gene can cause three phenotypically distinct cardiomyopathies: hypertrophic, restrictive, and dilated \[[@B10], [@B17]--[@B19]\]. *TNNT2*mutations are responsible for approximately 15% of all cases of familial hypertrophic cardiomyopathy (HCM) \[[@B20]--[@B22]\]. Recent data indicated that *TNNT2* mutations are also associated with DCM, and the overall frequency of *TNNT2* mutations in familial DCM is approximately 3--6% \[[@B23], [@B24]\].

Single nucleotide polymorphisms (SNPs) are the most common type of genetic variation in the human genome, and two recent large-scale SNP screens in European patients with DCM showed that SNPs in several genes were associated with DCM \[[@B26], [@B27]\]. Based on the above findings, we hypothesized that some cases of DCM are associated with specific polymorphisms in the *TNNT2* gene. To test this hypothesis and further understand the pathogenesis of DCM, we investigated 10 tagging SNPs in the *TNNT2* gene in DCM patients and normal control subjects from a Chinese Han population using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) techniques. Our results indicated that the SNPs rs3729547 and rs3729843 in the *TNNT2* gene were associated with DCM in the Chinese population, suggesting that the *TNNT2* polymorphisms may play an important role in susceptibility to DCM in the Chinese population.

2. Materials and Methods {#sec2}
========================

2.1. Subjects and Selection of Tagging SNPs {#sec2.1}
-------------------------------------------

This case-control study enrolled 97 unrelated DCM patients from the Fuwai Hospital. The clinical diagnosis was made in accordance with the revised criteria \[[@B1]\]. A total of 189 healthy unrelated individuals from a routine health survey were enrolled as controls. Patients with a history of hypertension, coronary heart disease, cardiac valve disease, diabetes, acute viral myocarditis, systemic diseases of putative autoimmune origin, and family history of DCM were intentionally excluded. This study was approved by the Ethics Committee of our hospital; the subjects involved were all of Han nation in the North of China and were informed of the study aims and provided written informed consent prior to participating.

Genotype data on the *TNNT2* gene from the Han Chinese in Beijing (CHB) population were downloaded from the phase 2 HapMap SNP database (available at <http://www.hapmap.org/>), and tagging SNPs were selected in the Haploview software (available at <http://www.broadinstitute.org/haploview>) using a minor allele frequency (MAF) cutoff of 0.05 and a correlation coefficient (*r* ^2^) threshold of 0.8.

2.2. Isolation of DNA and Genotyping by MALDI-TOF-MS {#sec2.2}
----------------------------------------------------

Blood samples were collected from patients using tubes containing ethylenediaminetetraacetic acid. Genomic DNA was isolated from whole blood with a QIAamp DNA Blood Mini Kit (Qiagen, Germany). Genotyping was performed by MALDI-TOF-MS as described previously \[[@B28]\]. SNP genotyping was performed using a MassARRAY system (Sequenom, San Diego, CA, USA) based on the MALDI-TOF-MS method, according to the manufacturer\'s instructions. Completed genotyping reactions were spotted onto spectroCHIP (Sequenom) using a MassARRAY Nanodispenser (Sequenom), and the genotype was determined by MALDI-TOF-MS. Genotype calling was performed in real time with MassARRAY RT software version 3.1 (Sequenom) and analyzed using MassARRAY Typer software version 4.0 (Sequenom) ([Table 1](#tab1){ref-type="table"}).

2.3. Statistical Analyses {#sec2.3}
-------------------------

Differences in the distributions of selected variables and *TNNT2*genotypes between the cases and controls were evaluated using the *χ* ^2^ test. The correlations between the *TNNT2*genotype and the risk of DCM were estimated by computing the odds ratios (ORs) and the 95% confidence intervals (CIs) using logistic regression analysis. The *χ* ^2^ test was used to test for the Hardy-Weinberg equilibrium to compare the observed and expected genotype frequencies among the control subjects. All statistical analyses were performed with SPSS 13.0. All tests were two-tailed, and the significance was set at *P* \< 0.05.

3. Results {#sec3}
==========

The gender and age distributions of the DCM patients and the control subjects were compared with the Pearson\'s chi-square test and Student\'s *t*-test, respectively, and no significant differences were detected (control: *n* = 189, 54.0 ± 3.6 years, male/female = 150/39; DCM: *n* = 97, 51.6 ± 12.0 years, male/female  =  75/22, *P* \> 0.05).

The observed and expected genotype frequencies of each SNP were compared with the chi-squared test in DCM patients and the control subjects separately, and no significance was detected in either group. These results indicate that the samples fit the assumption of the Hardy-Weinberg equilibrium. The DNA variants and the Hardy-Weinberg equilibrium test of the 10 tagging SNPs in the DCM patients and control subjects were shown in [Table 2](#tab2){ref-type="table"}.

Using the chi-squared test, we compared the genotype and allele frequencies in the *TNNT2* gene between the DCM patients and control subjects. Our results showed that the allele frequencies of the tagging SNPs rs3729547 (*χ* ^2^ = 5.474,  *P* = 0.019), rs1892028 (*χ* ^2^ = 5.855,   *P* = 0.016), rs3729843 (*χ* ^2^ = 9.620,  *P* = 0.002), rs12564445 (*χ* ^2^ = 4.351, *P* = 0.037), and rs10800775 (*χ* ^2^ = 4.252,  *P* = 0.039) were significantly correlated with DCM. However, among the genotypes, only those of the tagging SNPs rs3729547 (*χ* ^2^ = 6.63,   *P* = 0.036,  OR = 0.650, 95% CI = 0.453--0.934) and rs3729843 (*χ* ^2^ = 9.787,  *P* = 0.008, OR = 1.912, 95% CI = 1.265--2.890) had a significant correlation with DCM in the Chinese population. The allele and genotype frequencies of the ten tagging SNPs in the DCM patients and control subjects and the statistical analysis results were shown in [Table 3](#tab3){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}.

Because the great majority of DCM patients are male \[[@B1]--[@B5]\], we compared the frequencies of the genotypes of SNPs rs3729547, rs3729843, and rs10927875 in *TNNT2*between the DCM patients and control subjects stratified by gender. In males, the distributions of the SNP rs3729547 genotypes were not significantly different between the DCM patients and control subjects, but the distributions of the SNP rs3729843 genotype were significantly different in the DCM patients and control subjects (*χ* ^2^ = 8.102, *P* = 0.017). In females, the distributions of the genotypes of rs3729843 and rs3729547 were not significantly different in the DCM patients and control subjects.

The nonrandom associations between polymorphic variants at different loci on the *TNNT2* gene were then measured by the degree of linkage disequilibrium (LD). LD analysis showed that the SNPs rs7521796, rs2275862, rs3729547, rs10800775, and rs1892028 in the *TNNT2* gene, which are approximately 6 kb apart (block 3, [Figure 2](#fig2){ref-type="fig"}), were in high LD in the DCM patients ([Figure 2](#fig2){ref-type="fig"}, *D*′ \> 0.80). The haplotype analysis showed that ACTCA (*χ* ^2^ = 6.66, *P* = 0.0099) and AGCTG (*χ* ^2^ = 4.003, *P* = 0.0454) in block 3 and AG (*χ* ^2^ = 3.988, *P* = 0.0458) in block 4 (rs12564445 and rs4915232) of the *TNNT*2 gene correlated significantly with DCM ([Figure 2](#fig2){ref-type="fig"}, [Table 4](#tab4){ref-type="table"}).

4. Discussion {#sec4}
=============

To our knowledge, this is the first study to show an association between DCM and SNPs in the *TNNT2* gene in the Chinese population. DCM is regarded as a heterogeneous disease. The present study shows that, in at least a subgroup of DCM patients, the SNPs in the *TNNT2* (rs3729547 and rs3729843) gene may be involved in the pathogenesis of DCM.

DCM represents the third most frequent cause of heart failure and the most frequent cause of heart transplantation. Among patients with the so-called idiopathic DCM, 20--50% of cases are of genetic origin \[[@B6], [@B7]\]. Over the past decade, de novo mutations have been found in more than 30 genes encoding essential sarcomeric, cytoskeletal, and nuclear proteins in DCM patients \[[@B29]\], and mutations in the *TNNT2* gene have been found to be associated with familial HCM and DCM \[[@B10], [@B17]--[@B19], [@B23], [@B24]\].

Recent studies have suggested that cardiac TnT is essential not only for the structural integrity of the troponin complex but also for sarcomere assembly and cardiac contractility \[[@B22]\]. The troponin complex is a calcium sensor that regulates the contraction of striated muscle, and TnT is important in mediating the interaction between tropomyosin and actin and the rest of the troponin complex, which appears to modulate the activation of actomyosin ATPase activity and force \[[@B30]\]. Countless studies in reconstituted systems have provided valuable information on the functional effects of disease-associated mutations in TnT. The most extensively studied DCM-associated TnT mutation to date is ΔK210; functional studies of the ΔK210 mutation showed that the mutated protein reduced the Ca^2+^ sensitivity of actomyosin ATPase activity, which resulted in a decreased maximum speed of muscle contraction \[[@B31], [@B32]\]. Thus, DCM mutations in the troponin complex may induce a profound reduction in force generation, leading to impaired systolic function and cardiac dilation.

In this study, we assessed whether polymorphism within the *TNNT2* gene might affect DCM susceptibility by comparing ten tagging SNP loci in DCM patients and normal control subjects. The representative SNP in a region of the genome with high linkage disequilibrium is called a tagging SNP. Among the ten tagging SNPs in the *TNNT2* gene, we found a significant association between the genotypes of rs3729547 (synonymous variant) and rs3729843 (noncoding SNP) and DCM. Although the allele frequencies of five tagging SNPs (rs3729547, rs3729843, rs1892028, rs1256445, and rs10800775) were significantly associated with DCM, the genotypes of rs1892028, rs1256445, and rs10800775 were not significantly associated with DCM, possibly because of the limited number of patients enrolled in the present study. LD analysis of the polymorphic SNPs observed in our study revealed a group of five SNPs, rs7521796, rs2275862, rs3729547, rs10800775, and rs1892028, located 6 kb apart; these alleles were in high LD and associated with DCM risk. As the majority of SNPs are likely to be allelic variants that do not affect expression or function of a protein, such SNPs are commonly used as genetic markers to localize nearby disease-causing variations in linkage and association analyses. SNPs that directly influence phenotype may be located within coding or regulatory regions of genes. SNPs within regulatory regions tend to have more quantitative effects, for example, by altering the expression level of a receptor or signaling protein, and result in a more subtle variation in the associated phenotype \[[@B33]\]. Recently, study showed that polymorphism in intron 3 of *TNNT2* significantly affected the mRNA expression pattern by skipping exon 4 during splicing in cardiomyopathy patients \[[@B34]\]. Missing exon 4 in cardiac troponin T is corresponding to isoforms cTnT2 and cTnT4, and the two isoforms increase might be related to hemodynamic stress \[[@B35]\]. These results in our study suggest that *TNNT2*gene polymorphism, as like genetic markers to localize nearby disease-causing variations in linkage and association analyses, may play an important role in DCM susceptibility in the Chinese Han population. However, further functional analyses are needed to confirm the role of these polymorphisms in the pathogenesis of DCM.

In the present study, we have provided the evidence that shows that SNPs in the *TNNT2* gene may be implicated in the pathogenesis of DCM in a Chinese population. However, because the frequencies of genetic polymorphisms vary greatly among ethnic populations, further studies in other populations are needed to exclude a population-oriented association. In addition, the outcomes of the present study may be influenced by the limited sample size; larger studies are therefore required to investigate the potential associations between the SNPs in the*TNNT2* gene and the DCM susceptibility.
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![Mapping of the significance of each tagging SNP in the *TNNT2* gene. The *x*-axis shows the genomic position, and the *y*-axis shows the negative logarithm of the *P* value for each allele or genotype of each SNP.](BMRI2013-201372.001){#fig1}

![Pairwise linkage disequilibrium (LD) values calculated between tagging SNPs in the *TNNT2* gene. The value within each diamond represents the pairwise correlation between tagging SNPs (measured as *D*′), defined by the upper left and the upper right sides of the diamond. The diamond without a number corresponds to *D*′ = 1. Shading represents the magnitude and significance of the pairwise LD with darker red reflecting higher LD values and white indicating lower LD values.](BMRI2013-201372.002){#fig2}

###### 

Sequences of the PCR primers used to genotype SNPs in the DCM patients and control subjects.

  Markers      Forward primer (5′-3′)   Reverse primer (5′-3′)   Amplicon size (bp)   Temp. (°C)   GC (%)
  ------------ ------------------------ ------------------------ -------------------- ------------ --------
  rs7521796    TGCCAACAGAGAGGTGCTTC     CTTGAGGCTCAGCCTAATTG     93                   46.5         56.3
  rs2275862    AATATGAGGTGGGCCGCCAT     TATTACCGGACCCAGTGAAC     99                   48.4         52.9
  rs3729547    GAAGGACCTGAATGAGTTGC     AGAAACGAGCTCCTCCTCCT     99                   50.2         60
  rs10800775   AATCCCCTCCCAGGTCTTTG     TCATGTCATCAGCTTCTGCC     98                   50.7         47.4
  rs1892028    AGAGGGGACCATTGTCCAG      TCTAGGAGCTTCATGTGTGG     100                  48           62.5
  rs3729843    TCAAGGTCCTTGTTCTGAGC     TCTTGGCTAGGGCTTATCTG     99                   47.1         44.4
  rs3729842    TCAACGTTTGTTGATTGGGC     AGAACAGGCTTTCCCATGTG     99                   46.7         31.8
  rs12563114   TGGAAGGGCAGAGTAGGAGA     AATTCTCAGAGGAACCGTGC     100                  45.2         44.4
  rs12564445   AACTCGGAGACTGTTTCTAC     CTCTCTGACTTCAGTTAACC     95                   47.7         47.1
  rs4915232    CAATCTCGCTATTCTCTGCC     AGAAGAGTTTGAGGACTGGG     95                   48.6         62.5

###### 

Identified DNA variants and the Hardy-Weinberg equilibrium of 10 SNPs in the *TNNT2* gene in the DCM patients and control subjects.

  Markers      Location of nucleotide change   Amino acid change      Note                      Obs HET   Expt HET   HWE (*P*)   MAF
  ------------ ------------------------------- ---------------------- ------------------------- --------- ---------- ----------- -------
  rs7521796    Intron 201330019 A\>G           Noncoding              Novel noncoding SNP       0.115     0.115      1           0.061
  rs2275862    Intron 201330366 C\>G           Non-coding             Novel non-coding SNP      0.329     0.319      0.7683      0.199
  rs3729547    201334382 T\>C                  Synonymous Ile \[I\]   Reported synonymous       0.504     0.484      1           0.41
  rs10800775   Intron 201336386 C\>T           Non-coding             Novel non-coding SNP      0.474     0.448      0.771       0.339
  rs1892028    Intron 201336641 A\>G           Non-coding             Novel non-coding SNP      0.489     0.498      0.7396      0.47
  rs3729843    Intron 201336984 G\>A           Non-coding             Reported non-coding SNP   0.285     0.331      0.5949      0.21
  rs3729842    Intron 201337170 C\>T           Non-coding             Reported non-coding SNP   0.225     0.241      0.3594      0.14
  rs12563114   Intron 201344908 C\>T           Non-coding             Novel non-coding SNP      0.081     0.084      0.5638      0.044
  rs12564445   Intron 201345487 G\>A           Non-coding             Novel non-coding SNP      0.435     0.427      0.7891      0.309
  rs4915232    5′ near gene 201347946 A\>G     Non-coding             Novel non-coding SNP      0.535     0.499      0.7407      0.482

Note: Obs HET: observed heterozygosity, Expt HET: expected heterozygosity, HWE (*P*): *P* value from the Hardy-Weinberg equilibrium test, and MAF: minor allele frequency.

###### 

Genotype and allele frequencies of the SNPs from the *TNNT2* gene in the DCM patients and control subjects.

  Marker       Genotype      *χ* ^2^, *P* value   Allele        *χ* ^2^, *P*value   OR (95% CI)                                    
  ------------ ------------- -------------------- ------------- ------------------- ------------- ------------- ------------------ ----------------------
  rs7521796    A/A           A/G                  G/G                               A             G                                1.303 (0.613--2.772)
  Patients     87 (0.897)    10 (0.103)           0 (0)         *χ* ^2^ = 0.747     184 (0.948)   10 (0.052)    *χ* ^2^ = 0.4751    
  Controls     165 (0.873)   23 (0.122)           1 (0.005)     *P* = 0.688         353 (0.934)   25 (0.066)    *P* = 0.4906        
  rs2275862    C/C           C/G                  G/G                               C             G                                1.562 (0.987--2.471)
  Patients     69 (0.711)    26 (0.268)           2 (0.021)     *χ* ^2^ = 3.802     164 (0.845)   30 (0.155)    *χ* ^2^ = 3.669     
  Controls     113 (0.598)   68 (0.360)           8 (0.042)     *P* = 0.149         294 (0.778)   84 (0.222)    *P* = 0.055         
  rs3729547    C/C           T/C                  T/T                               C             T                                0.650 (0.453--0.934)
  Patients     8 (0.084)     49 (0.516)           38 (0.4)      *χ* ^2^ = 6.63      65 (0.342)    125 (0.658)   *χ* ^2^ = 5.474     
  Controls     37 (0.196)    94 (0.497)           58 (0.307)    **P** = 0.036       168 (0.444)   210 (0.556)   **P** = 0.019       
  rs10800775   C/C           C/T                  T/T                               C             T                                1.486 (1.019--2.169)
  Patients     47 (0.49)     44 (0.458)           5 (0.052)     *χ* ^2^ = 5.024     138 (0.719)   54 (0.281)    *χ* ^2^ = 4.252     
  Controls     74 (0.392)    91 (0.481)           24 (0.127)    *P* = 0.081         239 (0.632)   139 (0.368)   **P** = 0.039       
  rs1892028    A/A           A/G                  G/G                               A             G                                1.578 (1.090--2.291)
  Patients     30 (0.357)    42 (0.5)             12 (0.143)    *χ* ^2^ = 5.947     102 (0.607)   66 (0.393)    *χ* ^2^ = 5.855     
  Controls     46 (0.253)    88 (0.484)           48 (0.264)    *P* = 0.051         180 (0.495)   184 (0.505)   **P** = 0.016       
  rs3729843    A/A           A/G                  G/G                               A             G                                1.912 (1.265--2.890)
  Patients     12 (0.126)    30 (0.316)           53 (0.558)    *χ* ^2^ = 9.787     54 (0.284)    136 (0.716)   *χ* ^2^ = 9.620     
  Controls     7 (0.037)     51 (0.270)           131 (0.693)   **P** = 0.008       65 (0.172)    313 (0.828)   **P** = 0.002       
  rs3729842    C/C           C/T                  T/T                               C             T                                1.158 (0.697--1.925)
  Patients     74 (0.763)    21 (0.216)           2 (0.021)     *χ* ^2^ = 0.381     169 (0.871)   25 (0.129)    *χ* ^2^ = 0.322     
  Controls     139 (0.739)   43 (0.229)           6 (0.032)     *P* = 0.827         321 (0.854)   55 (0.146)    *P* = 0.571         
  rs12563114   C/C           C/T                  T/T                               C             T                                0.899 (0.390--2.07)
  Patients     87 (0.906)    9 (0.094)            0 (0)         *χ* ^2^ = 0.828     183 (0.953)   9 (0.047)     *χ* ^2^ = 0.063     
  Controls     174 (0.921)   14 (0.074)           1 (0.005)     *P* = 0.661         362 (0.958)   16 (0.042)    *P* = 0.8022        
  rs12564445   A/A           A/G                  G/G                               A             G                                0.663 (0.450--0.977)
  Patients     6 (0.062)     37 (0.381)           54 (0.557)    *χ* ^2^ = 4.503     49 (0.253)    145 (0.747)   *χ* ^2^ = 4.351     
  Controls     20 (0.106)    87 (0.463)           81 (0.431)    *P* = 0.105         127 (0.338)   249 (0.662)   **P** = 0.037       
  rs4915232    A/A           A/G                  G/G                               A             G                                1.155 (0.816--1.635)
  Patients     25 (0.258)    55 (0.567)           17 (0.175)    *χ* ^2^ = 1.385     105 (0.541)   89 (0.459)    *χ* ^2^ = 0.6590    
  Controls     46 (0.246)    97 (0.519)           44 (0.235)    *P* = 0.500         189 (0.505)   185 (0.495)   *P* = 0.4170        

###### 

Haplotype analysis of SNPs in *TNNT2* gene between the DCM patients and control subjects.

            Haplotype   Frequency (DCM patients)   Frequency (control subjects)   *χ* ^2^      *P*value
  --------- ----------- -------------------------- ------------------------------ ------------ ------------
  Block 1   ACTCA       0.604                      0.489                          6.66         **0.0099**
  AGCTG     0.145       0.215                      4.003                          **0.0454**   
  ACCTG     0.136       0.150                      0.208                          0.6485       
  ACCCG     0.058       0.070                      0.312                          0.5762       
  GCTCG     0.052       0.066                      0.436                          0.5089       
  Block 2   GA          0.541                      0.498                          0.937        0.333
  AG        0.252       0.333                      3.988                          **0.0458**   
  GG        0.207       0.163                      1.699                          0.1925       
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